Latest Australian Government News

5G Networks has reported a strong FY25 with an 8% revenue increase and a positive EBITDA turnaround, driven by the strategic acquisition of cyber security firm AUCyber. The company’s expansion into sovereign cloud services signals a new growth chapter.

Papyrus Australia reported a July 2025 cash flow update showing a stable cash position of AUD 303,000 and available funding supporting operations for over eight months. The company continues to manage its financing facilities prudently while navigating operational expenses.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

Radiopharm Theranostics reported a dramatic revenue surge to $3.63 million alongside a 20% reduction in net loss for FY2025, while increasing its stake in Radiopharm Ventures to 75%.

Warriedar Resources reports encouraging assay results from 20 drillholes at its Golden Range Project, confirming extensions of gold mineralisation beyond current estimates at the M1 deposit and validating historical data at Valencia.

PPK Group reported a statutory loss in FY25 driven by a significant non-cash impairment of its lithium-sulfur battery investment, while its ballistics division achieved record revenue and battery sales gained momentum from government programs.

Wellard Limited reported a net profit of US$1.3 million for FY2025, driven by operational improvements and strategic asset sales. With the sale of its last livestock vessels completed, the company plans to delist from the ASX and return surplus cash to shareholders.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

HPP has agreed to acquire Red Earth Energy Storage in a $40 million merger, aiming to relist on the ASX by early 2026 and capitalize on Australia’s growing battery storage market.

Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.

Tetratherix Limited reports its first financial results as a listed company, revealing a $9.4 million statutory loss driven by R&D and listing costs, alongside a robust $29.3 million cash position post-IPO. The company highlights key operational milestones and outlines strategic plans to accelerate commercialisation across its innovative biomaterial platform.

Tetratherix Limited reported a $9.4 million statutory loss for FY25 amid significant R&D and operational investments, successfully listing on the ASX and progressing multiple clinical and manufacturing initiatives.